Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Fall;11(Suppl 1):S9-S13.

Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease

Herbert Lepor  1
Affiliations

Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease

Herbert Lepor. Rev Urol. 2009 Fall.

Abstract

The medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating alpha-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both alpha-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of alpha-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.

Keywords: Benign prostatic hyperplasia; Bladder outlet obstruction; Lower urinary tract symptoms; Selectivity; α-Adrenoceptors; α-Blockers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
New concepts in drug development of α-blockers. AR, androgen receptor; BOO, bladder outlet obstruction; LUTS, lower urinary tract symptoms. Data from Roehrborn CG and Schwinn DA and Schwinn DA and Roehrborn CG.
See this image and copyright information in PMC

References

    1. Caine M, Pfau A, Perlberg S. The use of alphaadrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255–263. - PubMed
    1. Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo-controlled study. J Urol. 1975;114:564–568. - PubMed
    1. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986;136:1–4. - PubMed
    1. Shapiro E, Becich MJ, Lepor H. The relative proportion of stromal and epithelial hyperplasia as related to the development of clinical BPH. J Urol. 1992;147:1293–1297. - PubMed
    1. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992;21:297–307. - PubMed

LinkOut - more resources